<DOC>
	<DOCNO>NCT01723514</DOCNO>
	<brief_summary>The primary purpose study determine whether AMG 334 safe well tolerate healthy subject migraine patient . As part secondary objective , study conduct characterize pharmacokinetic ( PK ) profile AMG 334 multiple SC dose healthy subject migraine patient , well characterize effect AMG 334 capsaicin induced increase dermal blood flow multiple SC dose healthy subject migraine patient .</brief_summary>
	<brief_title>Ascending Multiple-Doses AMG 334 Healthy Subjects Migraine Patients</brief_title>
	<detailed_description>In ascend multiple dose , double blind , placebo control study , total 40 subject randomize 5 cohort . Approximately 24 HS randomize 3 cohort ( A1 , A2 , A3 ) , 16 migraine patient randomize 2 cohort ( B1 B2 ) . Each subject receive total 3 SC dos AMG 334 placebo .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Healthy male female subject , well male female subject migraines 18 55 year age , inclusive , history evidence clinically relevant medical disorder determine investigator consultation Amgen physician ; History evidence clinically significant disorder ( include psychiatric ) , condition disease , opinion Investigator Amgen physician would pose risk subject safety interfere study evaluation , procedure , completion ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Migraine</keyword>
</DOC>